[go: up one dir, main page]

NO20053483L - 4-Anilinokinazolinderivater for behandling av unormal cellevekst - Google Patents

4-Anilinokinazolinderivater for behandling av unormal cellevekst

Info

Publication number
NO20053483L
NO20053483L NO20053483A NO20053483A NO20053483L NO 20053483 L NO20053483 L NO 20053483L NO 20053483 A NO20053483 A NO 20053483A NO 20053483 A NO20053483 A NO 20053483A NO 20053483 L NO20053483 L NO 20053483L
Authority
NO
Norway
Prior art keywords
formula
cell growth
abnormal cell
treatment
compound
Prior art date
Application number
NO20053483A
Other languages
English (en)
Other versions
NO20053483D0 (no
Inventor
Zhengyu Liu
John Charles Kath
Maria Steflik Brown
Steven Mark Winter
Susan Jane Truesdell
Ruby Anthea Szewc
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20053483D0 publication Critical patent/NO20053483D0/no
Publication of NO20053483L publication Critical patent/NO20053483L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel 1 og farmasøytisk akseptable salter, prodrugs og solvater derav der R1, R2, R3 og R4 er som definert her, og der forbindelsen med formel 1 eventuelt videre omfatter en hydroksysubstitutent eller en O-glukuronsyre. Det beskrives videre metoder for behandling av abnormal cellevekst i pattedyr ved å administrere forbindelsen med formel I og det beskrives farmasøytiske preparater for behandling av slike lidelser som inneholder forbindelsene med formel 1. Videre beskrives det metoder for å fremstille forbindelsen med formel 1.
NO20053483A 2002-12-18 2005-07-18 4-Anilinokinazolinderivater for behandling av unormal cellevekst NO20053483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43448602P 2002-12-18 2002-12-18
PCT/IB2003/005826 WO2004054585A1 (en) 2002-12-18 2003-12-08 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
NO20053483D0 NO20053483D0 (no) 2005-07-18
NO20053483L true NO20053483L (no) 2005-09-19

Family

ID=32595280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053483A NO20053483L (no) 2002-12-18 2005-07-18 4-Anilinokinazolinderivater for behandling av unormal cellevekst

Country Status (20)

Country Link
US (1) US20040254204A1 (no)
EP (1) EP1575592A1 (no)
JP (1) JP2006513179A (no)
KR (1) KR20050085749A (no)
CN (1) CN1729001A (no)
AR (1) AR042480A1 (no)
AU (1) AU2003303045A1 (no)
BR (1) BR0317433A (no)
CA (1) CA2510323A1 (no)
GT (1) GT200300286A (no)
MX (1) MXPA05006335A (no)
NL (1) NL1025044C2 (no)
NO (1) NO20053483L (no)
PA (1) PA8592801A1 (no)
PE (1) PE20040905A1 (no)
PL (1) PL377686A1 (no)
RU (1) RU2005119172A (no)
TW (1) TW200424190A (no)
WO (1) WO2004054585A1 (no)
ZA (1) ZA200504147B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
WO2006129168A2 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711783A1 (en) * 1994-11-08 1996-05-15 Glaxo, S.A. Antifungal Sordarin derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PL354323A1 (en) * 1999-09-21 2004-01-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
BR0017067A (pt) * 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
JP4044839B2 (ja) * 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
CN1639149A (zh) * 2001-11-30 2005-07-13 辉瑞产品公司 制备用于治疗异常细胞生长的取代的双环衍生物的方法
WO2003049740A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production

Also Published As

Publication number Publication date
NO20053483D0 (no) 2005-07-18
NL1025044C2 (nl) 2005-02-15
PL377686A1 (pl) 2006-02-06
BR0317433A (pt) 2005-11-16
AR042480A1 (es) 2005-06-22
ZA200504147B (en) 2006-07-26
PA8592801A1 (es) 2004-07-26
NL1025044A1 (nl) 2004-06-21
AU2003303045A1 (en) 2004-07-09
RU2005119172A (ru) 2006-01-20
KR20050085749A (ko) 2005-08-29
EP1575592A1 (en) 2005-09-21
TW200424190A (en) 2004-11-16
PE20040905A1 (es) 2005-01-18
JP2006513179A (ja) 2006-04-20
GT200300286A (es) 2004-08-13
US20040254204A1 (en) 2004-12-16
CN1729001A (zh) 2006-02-01
MXPA05006335A (es) 2005-08-26
CA2510323A1 (en) 2004-07-01
WO2004054585A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
CA2413424A1 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
NO20055143L (no) Doseringsformer innbefattende AG013736
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
CA2392973A1 (en) Benzoimidazole derivatives useful as antiproliferative agents
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20062370L (no) Amidderivater
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
CA2478374A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
NO20076138L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20015172L (no) 1-metyl-erytromycin-derivater
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20052182L (no) Nye forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application